

****Published June 2015****

MarketVIEW: Human metapneumovirus vaccines (CAT: VAMV062)

Product Name	:	MarketVIEW: Human metapneumovirus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 1 forecast model (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	June 2015
Catalogue No	:	VAMV062

Background

Human metapneumovirus (hMPV) is a member of the *Metapneumovirus* genus in the *Pneumovirinae* subfamily of the *Paramyxoviridae* family. The virus is transmitted between humans via direct or close contact and has a seasonality of infection similar to influenza and RSV. hMPV is the second most common cause of lower respiratory tract infections after RSV in young children. Most common causes for hospitalisation with hMPV are bronchiolitis and pneumonia. Mortality from hMPV occurs in 3.4–6.6% of hospitalised adults.

Because of its similarity to RSV and significant global morbidity and mortality, hMPV can be considered an attractive target for a new preventative vaccine.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of hMPV monovalent vaccines and bivalent vaccines (with RSV) across the seven major markets until 2035. The model contains value (\$ m) and volume (mio doses) predictions per vaccine type¹/per with BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations. The product also includes an in depth review of latest hMPV epidemiological trends, treatments/guidelines and latest developments in R&D. It discusses the pros and cons of pursuing a monovalent versus bivalent approach.

¹ Live attenuated vaccines, subunit vaccines

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to human metapneumovirus and related respiratory pathogens e.g. RSV. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of novel vaccines has also been utilised.

PRODUCT CONTENTS:

Published June 2015 (CAT No: VAMV062)

****This product is composed of one forecast model (.xls) and a summary presentation (.pdf)

Author's note

Contents

Executive summary

Executive summary: monovalent or bivalent strategy?

Commercial model: key model outputs

Human metapneumovirus vaccines: global forecast revenue per scenario (all, \$m) to 2035

Human metapneumovirus vaccines: global forecast volume per scenario (all, 000s doses) to 2035

hMPV vaccines: Base scenario (monovalent) volume and value by segment to 2035

hMPV vaccines: High scenario (bivalent) volume and value by segment to 2035

hMPV vaccines: Base scenario (monovalent) volume and value by country to 2035

hMPV vaccines: High scenario (bivalent) volume and value by country to 2035

hMPV vaccines: country market share by volume and value in 2035

hMPV vaccines: volume (000s) for the adult segment by group

hMPV vaccines: value share for the adult segment by group

Commercial summary: hMPV monovalent vs bivalent vaccines

Human metapneumovirus: Disease background and epidemiology

Human metapneumovirus: the pathogen

Geographical distribution of hMPV serotypes

Transmission and seasonality of hMPV

Diagnosis of hMPV

Clinical presentation of hMPV

Epidemiology of hMPV

Morbidity and mortality associated with hMPV

Risk factors for hMPV and severe hMPV

Economic burden of hMPV

hMPV and respiratory syncytial virus: comparison and coinfection

hMPV and RSV: disease parameters comparison

Risk factors for hMPV and RSV are similar

RSV and hMPV: age and probability of infection

Treatment strategies for hMPV

hMPV: treatment strategies under development

hMPV: treatment strategies under development (cont..)

Vaccination against hMPV: rationale and approaches

Unmet need for an hMPV vaccine and historical approaches

Approaches to hMPV vaccination (1): inactivated vaccines

Continued.....

Approaches to hMPV vaccination (1): inactivated vaccines (cont..)
Approaches to hMPV vaccination (2): live attenuated vaccines (LAVs)
Approaches to hMPV vaccination (3): subunit vaccines
Approaches to hMPV vaccination (4): virus-like particle (VLP) vaccines and recombinant BCG vaccines
Approaches to hMPV vaccination (5): epitope vaccines
Key factors in hMPV vaccine development
hMPV vaccines in development: Overview of current R&D
Chimeric rhMPV-Pa (NIAID)
ViroNovative
Vanderbilt University
hMPV vaccines: R&D pipeline
Possibility of creating multivalent hMPV and RSV (and PIV) vaccines
hMPV vaccines: Target product profiles
hMPV vaccines: monovalent vaccine target product profile (TPP)
hMPV vaccines: bivalent vaccine target product profile (TPP)
hMPV vaccines: modelling commercial potential
Modelling scenarios: Base (monovalent vaccine)
Modelling scenarios: High (bivalent vaccine)
Modelling scenarios: summary
Recommendation/reimbursement
Pricing: infant immunisation (monovalent, Base model)
Pricing: adult immunisation (monovalent, Base model)
Pricing: bivalent vaccine (High model)
Methodology: populations
Methodology: coverage
Modelling: summary of start/peak coverage rates (US)
Model limitations and caveats
Influenza immunisation rates amongst eligible people in the 5EU countries⁵⁴
RSV vaccine development pipeline (PATH)
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~75 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Title sheet
Scenario definitions
CHARTS (summary)
CHARTS (countries)
CHARTS (adult segments)
Value summary (base)
Volume summary (base)
Value summary (high)
Volume summary (high)

Continued.....

Pricing summary
Base scenario
Country volume worksheets
US (base)
Canada (base)
France (base)
Germany (base)
Italy (base)
Spain (base)
UK (base)
Country populations
US
Canada
France
Germany
Italy
Spain
UK
Source material
Births
18yrs+ population
65yrs+ population
Total population
Asthma COPD epidemiology
CHF epidemiology
Coverage (COPD and HF)
Back page
About **VacZine Analytics**
Disclaimer

Worksheets ~ 44 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5800.00**# (Region license)*
- PRESENTATION OR MODEL ONLY - USD **\$4995** (Region license)*

Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. Haas LE, et al. Human Metapneumovirus in Adults. *Viruses*. 2013;5:87.
2. Panda S, et al. Human metapneumovirus: review of an important respiratory pathogen. *Int. J. Infect. Dis.* 2014;25:45.
3. Peret TC, et al. Characterization of Human Metapneumoviruses Isolated from Patients in North America. *J. Infect. Dis.* 2002;185:1660.
4. CDC. Human Metapneumovirus (HMPV) National Trends. 2015. <http://www.cdc.gov/surveillance/nrevss/hmpv/natl-trend.html> [Accessed April 2015].
5. Pilger DA, et al. Detection of human bocavirus and human metapneumovirus by real-time PCR from patients with respiratory symptoms in Southern Brazil. *Mem. Inst. Oswaldo Cruz.* 2011;106:56.
6. Reiche J, et al. Human Metapneumovirus: Insights from a Ten-Year Molecular and Epidemiological Analysis in Germany. *PLoS One.* 2014;9(2):e88342.
7. Principi N, Esposito S. Paediatric human metapneumovirus infection: Epidemiology, prevention and therapy. *J. Clin. Virol.* 2014;59:141.
8. Edwards KM, et al. Burden of Human Metapneumovirus Infection in Young Children. *N. Engl. J. Med.* 2013;368:633.
9. Walsh EE, et al. Another Piece of the Puzzle: Human Metapneumovirus Infections in Adults. *Arch. Intern. Med.* 2008;168:2489.
10. Spaeder MC, et al. A multicenter outcomes analysis of children with severe viral respiratory infection due to human metapneumovirus. *Pediatr. Crit. Care Med.* 2013;14:268.
11. Seo YB, et al. Etiology and Clinical Outcomes of Acute Respiratory Virus Infection in Hospitalized Adults. *Infect. Chemother.* 2014;46:67.
12. Renaud C, et al. Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplant Recipients. *Biol. Blood Marrow Transplant.* 2013;19:1220.
13. ViroNovative. hMPV facts and figures. 2015. <http://vironovative.com/wp-content/uploads/2013/10/hMPV-Facts-and-Figures.pdf> [Accessed April 2015].
14. Wang Y, et al. Comparison of severe pneumonia caused by Human metapneumovirus and respiratory syncytial virus in hospitalized children. *Ind. J. Pathol. Microbiol.* 2014;57:413.
15. Widmer K, et al. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. *Influenza Other Resp. Viruses.* 2014;8:347.
16. Debiaggi M, et al. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. *Virol. J.* 2012;9:247
17. Greensill J, et al. Human Metapneumovirus in Severe Respiratory Syncytial Virus Bronchiolitis. *Emerg. Infect. Dis.* 2003;9:372.
18. Eggleston HA, et al. A comparison of characteristics and outcomes in severe human metapneumovirus and respiratory syncytial virus infections in children treated in an intensive care unit. *Pediatr. Infect. Dis. J.* 2013;32:1330.
19. Papenburg J, et al. Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children. *J. Infect. Dis.* 2012;206:178.
20. Walsh EE, Falsey AR. Respiratory Syncytial Virus Infection in Adult Populations. *Infect. Disord. Drug Targets.* 2012;12:98.
21. Palavecino CE, et al. Immunization with a Recombinant Bacillus Calmette–Guerin Strain Confers Protective Th1 Immunity against the Human Metapneumovirus. *J. Immunol.* 2014;192:214.
22. Ren J, et al. Recent vaccine development for human metapneumovirus. *J. Gen. Virol.* 2015;Feb 9. pii: vir.0.000083. [Epub ahead of print]
23. Pham QN, et al. Chimeric Recombinant Human Metapneumoviruses with the Nucleoprotein or Phosphoprotein Open Reading Frame Replaced by That of Avian Metapneumovirus Exhibit Improved Growth In Vitro and Attenuation In Vivo. *J. Virol.* 2005;79:15114.
24. Clinicaltrials.gov. Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine. <https://clinicaltrials.gov/ct2/show/NCT01255410> [Accessed May 2015].
25. Herfst S, et al. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. *J. Gen. Virol.* 2008;89:1553.
26. Herfst S, et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. *Vaccine.* 2008;26:4224.
27. PR Newswire. MedImmune Licenses Rights to Newly Discovered Human Metapneumovirus. 2002. <http://www.prnewswire.com/news-releases/medimmune-licenses-rights-to-newly-discovered-human-metapneumovirus-76736132.html> [Accessed May 2015].
28. Vanderbilt Vaccine Center. Vaccines. 2015. <https://medschool.vanderbilt.edu/vvc/research/vaccines#> [Accessed May 2015].
29. Mok H, et al. An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats. *J. Virol.* 2008;82:11410.

30. Liu P, et al. A Live Attenuated Human Metapneumovirus Vaccine Strain Provides Complete Protection against Homologous Viral Infection and Cross-Protection against Heterologous Viral Infection in BALB/c Mice. *Clin. Vaccine Immunol.* 2013;20:1246.
31. Tang RS, et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. *Vaccine.* 2005;23:1657.
32. Tang RS, et al. Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3' Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity. *J. Virol.* 2003;77:10819.
33. Herfst S, et al. Recovery of Human Metapneumovirus Genetic Lineages A and B from Cloned cDNA. *J. Virol.* 2004;78:8264.
34. ViroNovative BV Patent applications. 2009. <http://www.fags.org/patents/assignee/vironovative-bv/> [Accessed May 2015].
35. CDC Vaccine Price List. 2015. <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html> Accessed May 2015.
36. Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. *Vaccine.* 2013;31:4347.
37. Rotavirus vaccine to be introduced for babies. Available at: <http://www.nhs.uk/news/2012/11/November/Pages/New-vaccine-to-prevent-rotavirus-diarrhoea-in-babies.aspx>. Accessed May 2015.
38. Meijboom MJ et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. *Vaccine.* 2012 Jun 29;30(31):4691-700.
39. Flu Vaccine Effectiveness: Questions and Answers for Health Professionals. 2013. <http://www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm>. Accessed May 2014.
40. Meijboom MJ et al. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. *Vaccine.* 2013 Dec 16;31(52):6254-60.
41. Blackwell DL, et al. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. *Vital Health Stat.* 10. 2012;260:1.
42. Mozaffarian D, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation.* 2015;131:e29.
43. Wong CY, et al. Trends in comorbidity, disability, and polypharmacy in heart failure. *Am. J. Med.* 2011;124:136.
44. Mascarenhas J, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. *Am. Heart J.* 2008;155:521.
45. Morbidity and Mortality Weekly Report (MMWR). Rotavirus Vaccination Coverage Among Infants Aged 5 Months --- Immunization Information System Sentinel Sites, United States, June 2006--June 2009. 2010;59:521.
46. Centers for Disease Control and Prevention (CDC). Seasonal influenza vaccination coverage among women who delivered a live-born infant - 21 states and New York City, 2009-10 and 2010-11 influenza seasons. *MMWR Morb. Mortal. Wkly. Rep.* 2013;62:1001.
47. Santos-Sancho JM, et al. Influenza vaccination coverage and uptake predictors among Spanish adults suffering COPD. *Hum. Vaccin. Immunother.* 2012;8:938.
48. Morbidity and Mortality Weekly Report (MMWR). Vaccination Coverage Among Persons with Asthma --- United States, 2010-2011 Influenza Season. 2013;62:973.
49. Ajani UA, et al. Examining the coverage of influenza vaccination among people with cardiovascular disease in the United States. *Am. Heart J.* 2005;149:2549.
50. Rodríguez-Rieiro C, et al. Vaccination coverage against 2009 seasonal influenza in chronically ill children and adults: analysis of population registries in primary care in Madrid (Spain). *Vaccine.* 2010;28:6203.
51. Harris K, Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. *Vaccine.* 2009;27:2335.
52. Lu PJ, et al. Seasonal influenza vaccination coverage among adult populations in the United States, 2005-2011. *Am. J. Epidemiol.* 2013;178:1478.
53. Dube E, et al. Seasonal influenza vaccination uptake in Quebec, Canada, 2 years after the influenza A(H1N1) pandemic. *Am. J. Infect. Control.* 2014;42:e55.
54. Preaud E, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. *BMC. Public Health.* 2014;14:813.
55. RSV vaccine snapshot. PATH. Available at: <http://sites.path.org/vaccinedevelopment/files/2011/12/RSV-snapshot-March2015.pdf>. Accessed May 2015

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009